No CVD Benefit With Omega-3 Fatty Acids
According to the Age-Related Eye Disease Study 2 (AREDS2: Published March 17, 2014
in JAMA Internal Medicine
A moderate
dose of long-chain omega-3 fatty acids supplementing
the diets of elderly patients failed to
reduce CVD risk.
Taking omega-3
fatty-acid supplements for nearly five years failed to reduce the incidence of CVD
mortality, MI, stroke, unstable angina, revascularization, CHF
hospitalizations, and resuscitated cardiac arrest.
The trial is an ancillary
study which includes 4203 men and women treated at US ophthalmology clinics.
As part of the
factorial-design randomized trial, individuals were treated with 350-mg
docosahexaenoic acid and 650-mg eicosapentaenoic acid (EPA) for 4.8
years. Approximately 20% of randomized participants had a history of CVD.
Participants
were also treated with the macular xanthophylls lutein and zeaxanthin to
determine impact on CV outcomes.
Regarding the
primary end point, a composite of CV mortality and morbidity, supplementation
with omega-3 fatty acids failed to provide any reduction in clinical events.
In terms of
secondary end points, which included multiple combinations of components of the
primary end point, there was also no reduction in events.